BCM
MRSN

Bridgeway Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Bridgeway Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,020
Closed -$956K – 1297
2024
Q2 		$956K Buy
19,020
+9,728
+105% +$703K 0.02% 700
2024
Q1 		$1.04M Hold
9,292
– – 0.02% 737
2023
Q4 		$539K Sell
9,292
-13,976
-60% -$562K 0.01% 922
2023
Q3 		$739K Buy
+23,268
New +$1.11M 0.02% 789
2020
Q1 		– Sell
-6,376
Closed -$913K – 1332
2019
Q4 		$913K Buy
6,376
+1,864
+41% +$136K 0.01% 762
2019
Q3 		$178K Buy
4,512
+2,520
+127% +$183K ﹤0.01% 1199
2019
Q2 		$202K Hold
1,992
– – ﹤0.01% 1177
2019
Q1 		$262K Buy
+1,992
New +$251K ﹤0.01% 1178

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return